Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report

Overview of attention for article published in Frontiers in oncology, January 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,543 followers.

New research: Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report: Vemurafenib and trametinib have a lot of successful… https://t.co/sc

25 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.